



Medicines & Healthcare products
Regulatory Agency

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

[REDACTED]

9 May 2024

MHRA reference: FOI2024/00071

Dear [REDACTED],

Thank you for your information request, which we received on 28 April. You asked for:

*I'm writing to you to ask if the following medications are harmful.
I recently read that Metformin was recently banned in the UK because of carcinogenic content, but it's still dispersed here. In fact, I was prescribed it last October. neither my GP nor pharmacist expressed concerns about it. For some reason, I instinctively reduced the dose myself. I made the discovery about the zuK ban, even though I'm not a medical person!*

With this harmful comedy of errors in mind, can I please ask if the following medications are permitted in the UK?

*Lanzol
Rosuvorstatin
Escitalopram
Mirap
Melatonin*

*Vorstatin
Epleron
Bisop
Entresto
Forxiga
Thiamine*

We have dealt with your request under the Freedom of Information Act 2000 (FOIA).



Medicines & Healthcare products Regulatory Agency

We confirm that we hold the information you have asked for, and we are disclosing this information in full. Please see our response concerning each of the medicines you have listed.

1. Lanzol:

No product licenses exist in the UK for a product called “Lanzol.” Product licenses do exist in the UK for the active ingredient in “Lanzol”, which is called lansoprazole. Further information on lansoprazole is available from the Summaries of Product Characteristics (SmPCs), Patient Information Leaflets (PILs) and Public Assessment Reports (PARs) available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=lansoprazole&page=1>

2. Rosuvorstatin:

No product licenses exist in the UK for a product called “Rosuvorstatin.” We are assuming that you are referring instead to the active ingredient “rosuvastatin”, which has granted product licenses in the UK. Further information on rosuvastatin is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=rosuvastatin&page=1>

3. Escitalopram:

Product licenses do exist in the UK for the active ingredient escitalopram. Further information on escitalopram is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=escitalopram&page=1>

4. Mirap:

No product licenses exist in the UK for a product called “Mirap.” Product licenses do exist in the UK for the active ingredient in “Mirap”, which is called mirtazapine. Further information on mirtazapine is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=mirtazapine&page=1>

5. Melatonin:

Product licenses do exist in the UK for the active ingredient melatonin. Further information on melatonin is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=melatonin&page=1>



Medicines & Healthcare products Regulatory Agency

6. Vorstatin:

No product licenses exist in the UK for a product called “Vorstatin.” The active ingredient name you have given could be misspelt, we cannot assume any specific product or active ingredient name from “Vorstatin.” We invite you to check the spelling of this medicine and search for the active ingredient name on the MHRA website to obtain any further information (SmPCs, PILs and PARs) we may hold on this. A link to the MHRA Product Portal is provided below:

<https://products.mhra.gov.uk/>

7. Epleron:

No product licenses exist in the UK for a product called “Epleron.” We are assuming that you are referring instead to the active ingredient “eplerenone”, which has granted product licenses in the UK. Further information on eplerenone is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=eplerenone&page=1>

8. Bisop:

No product licenses exist in the UK for a product called “Bisop.” Product licenses do exist in the UK for the active ingredient in “Bisop”, which is called bisoprolol fumarate. Further information on bisoprolol fumarate is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=bisoprolol+fumarate&page=1>

9. Entresto:

Product licenses do exist in the UK for a product called “Entresto.” Further information on Entresto is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=entresto&page=1>

10. Forxiga:

Product licenses do exist in the UK for a product called “Forxiga.” Further information on Forxiga is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=forxiga&page=1>

11. Thiamine:

Product licenses do exist in the UK for the active ingredient thiamine. Further information on thiamine is available from the SmPCs, PILs and PARs available for these products on the MHRA website. A link to these is provided below:

<https://products.mhra.gov.uk/search/?search=thiamine&page=1>



Medicines & Healthcare products Regulatory Agency

We hope this information is useful for you.

This concludes our response to your request.

If you have a query about this response, please contact us at

Please remember to quote the reference number at the top of this letter in any future communications. Details of your appeal rights are below.

Yours sincerely,

Healthcare, Quality and Access Group
Medicines and Healthcare products Regulatory Agency

Appeal rights

If you are dissatisfied with the handling of your request, you can ask us to conduct an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: foi.request@mhra.gov.uk

If you remain dissatisfied with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of a request unless the requester has first asked us to conduct an internal review.

The Information Commissioner can be contacted through their online webform at: <https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/>

Or in writing to: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>

If you re-use our information, you should include the following attribution, including a link to the OGL v3.0:

Medicines and Healthcare products Regulatory Agency, [name and date of publication], licensed under the [Open Government Licence](#).



Medicines & Healthcare products Regulatory Agency

For further information on the reproduction or re-use of MHRA information, please visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>.